LEO Pharma: LEO Pharma marks 1 year of Adtralza in Korea with long-term data showing gains in hard-to-treat atopic dermatitis

Nearly a year after launching Adtralza (tralokinumab) in Korea with reimbursement backing, LEO Pharma returned to the podium with new data it hopes will cement the drug's role in moderate-to-severe atopic dermatitis -- particularly in hard-to-treat regions like the head and neck.Adtralza, approved i